ncRNA basic information
ncRNA ID:
MI0000816
ncRNA Database:
miRBase
ncRNA Name:
miR-335
ncRNA Type:
miRNA
ncRNA Expression:
down-regulated
ncRNA Method:
qRT-PCR
ncRNA Target Gene:
PARP-1
ncRNA Pathway:
NF-kappaB pathway
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00515 (APRD00359)
Drug Name:
Cisplatin
Drug Method:
The role of miR-335 in the regulation of chemosensitivity and radiosensitivity of small cell lung cancer (SCLC) was investigated. miR-335 was significantly downregulated in multi-drug-resistant SCLC H69AR and H446DDP cells compared with parental cells as detected by qRT-PCR. Then, we demonstrated the negative correlation between miR-335 expression and the chemo-radiosensitivity of SCLC cells, including cell proliferation, cell clonality and cell apoptosis. In addition, miR-335 overexpression inhibited cell migration in vitro and tumor growth in vivo, whereas inhibition of miR-335 promoted cell migration and tumor growth. The underlying mechanism was further studied. Poly [ADP-ribose] polymerase 1 (PARP-1) was identified as a direct target gene of miR-335 in SCLC by bioinformatics analysis and validated via luciferase reporter assay. Overexpression of miR-335 decreased the expression of PARP-1 mRNA and protein, and NF-kappaB protein levels were correspondingly downregulated, thus regulating the chemo-radiosensitivity of SCLC.
Drug Response:
resistant
Cancer basic information
Cancer:
lung small cell carcinoma
Tissue/Cell:
cell line (H69AR, H446DDP)
Other information
Title:
MiR-335 regulates the chemo-radioresistance of small cell lung cancer cells by targeting PARP-1.
Journal:
Gene
Published:
2017
PubMed ID:
27871924